Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-12-22

Clinical Trial Update: Dupilumab in Allergic Fungal Rhinosinusitis (AFRS) (LIBERTY-AFRS-AI) [Phase 3]

View source ↗

Summary

Phase 3 trial results for dupilumab in allergic fungal rhinosinusitis have been completed and results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Dupilumab (dupilumab)

Snippet

Sponsor: Sanofi | Conditions: Allergic Fungal Rhinosinusitis | Phase 3 | Status: COMPLETED | Results posted: 2025-12-22